EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations

Meiying Shen, Siyin Chen, Xiaojian Han, Yanan Hao, Junfan Wang, Luo Li, Tong Chen, Bozhi Wang, Lin Zou, Tong Zhang, Wanli Zhang, Xiaxia Han und 5 weitere

Cancer Immunology, Immunotherapy · 2024

DOI: 10.1007/s00262-024-03729-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Meiying Shen und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Receptors, Antigen, T-Cell, Mutation, Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chongqing Postdoctoral Science Foundation, National Natural Science Foundation, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hotspot driver mutations presented by human leukocyte antigens might be recognized by anti-tumor T cells. Based on their advantages of tumor-specificity and immunogenicity, neoantigens derived from hotspot mutations, such as PIK3CA H1047L , may serve as emerging targets for cancer immunotherapies. NetMHCpan V4.1 was utilized for predicting neoepitopes of PIK3CA hotspot mutation. Using in vitro stimulation, antigen-specific T cells targeting the HLA-A*11:01-restricted PIK3CA mutation were isolated from healthy donor-derived peripheral blood mononuclear cells. T cell receptors (TCRs) were cloned using single-cell PCR and sequencing. Their functionality was assessed through T cell activation markers, cytokine production and cytotoxic response to cancer cell lines pulsed with peptides or transduced genes of mutant PIK3CA . Immunogenic mutant antigens from PIK3CA and their corresponding CD8 + T cells were identified. These PIK3CA mutation-specific CD8 + T cells were subsequently enriched, and their TCRs were isolated. The TCR clones exhibited mutation-specific and HLA-restricted reactivity, demonstrating varying degrees of functional avidity. Identified TCR genes were transferred into CD8 + Jurkat cells and primary T cells deficient of endogenous TCRs. TCR-expressing cells demonstrated specific recognition and reactivity against the PIK3CA H1047L peptide presented by HLA-A*11:01-expressing K562 cells. Furthermore, mutation-specific TCR-T cells demonstrated an elevation in cytokine production and profound cytotoxic effects against HLA-A*11:01 + malignant cell lines harboring PIK3CA H1047L . Our data demonstrate the immunogenicity of an HLA-A*11:01-restricted PIK3CA hotspot mutation and its targeting therapeutic potential, together with promising candidates of TCR-T cell therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Class I Phosphatidylinositol 3-KinasesReceptors, Antigen, T-CellMutationNeoplasmsHumansImmunotherapyHLA-A11 AntigenCD8-Positive T-LymphocytesEpitopes, T-LymphocyteAntigens, NeoplasmCell Line, Tumor

Stichwörter der Autor:innen

PIK3CAAnti-tumor immunotherapyEngineering TCR-THLA-A*11:01Neoantigen

Substanzen

Class I Phosphatidylinositol 3-KinasesReceptors, Antigen, T-CellPIK3CA protein, humanHLA-A11 AntigenEpitopes, T-LymphocyteAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
  • Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.
  • Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China.
  • Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. liushengchun1968@163.com.
  • Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. aishunjin@cqmu.edu.cn.
  • Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. aishunjin@cqmu.edu.cn.

Förderung

  • Chongqing Postdoctoral Science Foundation
  • National Natural Science Foundation, China

Zitieren

APA

Shen, M., Chen, S., Han, X., Hao, Y., Wang, J., Li, L., Chen, T., Wang, B., Zou, L., Zhang, T., Zhang, W., Han, X., Wang, W., Yu, H., Li, K., Liu, S., & Jin, A. (2024). Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03729-y

Vancouver

Shen M, Chen S, Han X, Hao Y, Wang J, Li L, et al. Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03729-y

BibTeX
@article{Shen2024,
  author = {Shen, Meiying and Chen, Siyin and Han, Xiaojian and Hao, Yanan and Wang, Junfan and Li, Luo and Chen, Tong and Wang, Bozhi and Zou, Lin and Zhang, Tong and Zhang, Wanli and Han, Xiaxia and Wang, Wang and Yu, Haochen and Li, Kang and Liu, Shengchun and Jin, Aishun},
  title = {Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2024},
  doi = {10.1007/s00262-024-03729-y}
}
Kostenlos starten →